InnoCare Pharma Doses First Subject in Phase 1 Trial of ICP-054, a Novel Oral IL-17AA/AF Inhibitor for Autoimmune Diseases 12
InnoCare Pharma Announces First Dosing in Phase 1 Trial of I...
Sign in to continue:
InnoCare Pharma Announces First Dosing in Phase 1 Trial of I...
Sihuan Pharmaceutical Announces Significant Share Repurchase...
ADICON Holdings Major Acquisition Progress Update ADIC...
Huaibei GreenGold Industry Investment Co., Ltd. - Supplement...
Shanghai Zhida Technology Development Co., Ltd. Announces Ma...
China ZhengTong Auto Services Announces Bulk Commodity Deriv...
Central China Real Estate Limited - April 2026 Unaudited Con...
XPeng Inc. Announces Board Meeting and Q1 2026 Results Relea...
CStone Pharmaceuticals Announces On-Market Share Repurchase ...
ITC Properties Group Limited: Completion of Placing of New S...